Skip to main content

Fiscal Wizard · Single-issue tearsheet

VRXA / Jun 21, 2026 Run #7354

VRXA

Veraxa Biotech AG

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.

Composite verdict

D 35.9 / 100
Bearish setup · Trend Following 1 driver · gates clear
  • Parabolic SAR Flip
Consider long put target Δ ~0.50 · ~35 DTE Bearish setup, Grade C → ITM put target

Industry rank 131st of 598 in Biotechnology

rescore-sweep
Technical synthesis
Bull 0%Evidence: Low · 1 signals100% Bear
Momentum Bearish 33Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

25.2 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Greenblatt EY 75
Greenblatt ROC 0
Return on Capital Employed 69
Free Cash Flow Yield 0
Return on Assets 65
Return on Equity 25

Technicals Neutral

46.6 / 100

Bearish setup leads (Parabolic SAR Flip). · 43 signals shown.

Strongest
Weakest
Parabolic SAR Flip 21

Risk Gates

0 blocking 2 caution

No active guards. 2 caution flags (visual only).

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Sloan Ratio Caution

Visual accruals-quality flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for VRXA.